CSI Market
Sign In | Register

Ensysce Biosciences Inc (ENSC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ENSC Annual Cash Flow →
This page allows investors to follow Ensysce Biosciences Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-3.56
Depreciation & amortization0.01
Amortization of Other Assets0.00
Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.01
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Interest Earned On Marketable Securities Held In Trust Account-
Accrued Interest-
Change In Fair Value Of Embedded Derivative-
Adjustment To Fair Value Of Financial Instruments-
Commitment Fee For Share Subscription Facility-
Issuance Costs Paid To Close Convertible Debt-
Induced Conversion Of Convertible Debt Expense-
Derivative Gain Loss On Derivative Net-
Change In Fair Value Of Liabilities Classified Warrants-
Loss On Issuance Of Convertible Notes-
Adjustments Issuance Costs For Convertible Notes-
Increase Decrease In Unbilled Receivable0.42
Change In Fair Value Of Liability Classified Warrants-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-1.66
Accrued Expense-0.01
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other1.29
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-3.50
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Interest Income Released From Trust Account For Franchise Taxes And Income Taxes-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-4.31
Proceeds From Sale Of Units Net Of Underwriting Discounts Paid-
Amounts Returned To Trust Account For Excess Redemptions Previously Withdrawn-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations4.31
Proceeds From Convertible Debt-
Proceeds From Related Party Debt-
Repayment Insurance Premiums-0.06
Proceeds From Related Party Debt One-
Transaction Costs From Public Offering-
Proceeds From Warrant Inducement Net Of Issuance Costs-
Transaction Costs From Public Offerings-
Transaction Cost Associated With Warrant Inducement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.06
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-3.50
Total Cash Flow-3.56
4 historic quarters locked

Sign in to unlock the full Ensysce Biosciences Inc cash flow history.

Sign In Create Free Account

About Ensysce Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037817

Figures are derived from filed reports and may be restated. Historical data is subject to revision.